Biotech IV Monitor

NKTR — Nektar Therapeutics

$2.4B market cap · 2 upcoming readouts tracked

Clinical trial readout dates for Nektar Therapeutics, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is May 2028.

Next readoutMay 2028in ~18 months
Upcoming readouts22 Phase 3
Market cap$2.4B
Cash & investments$945M~17 quarters at last loss rate
Recent 8-K filings2latest 2026-11-13

Upcoming readouts

Phase 3 Rezpegaldesleukin
Moderate-to-Severe Atopic Dermatitis · NCT07690371
May 2028
Recruiting
Phase 3 Rezpegaldesleukin
Moderate-to-Severe Atopic Dermatitis · NCT07711418
June 2028
Recruiting

Cash position

Nektar Therapeutics reported $945M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-13). Its net loss for that quarter was $56M; at that rate the cash would last about 17 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Reg FD Disclosure — often a data announcement2026-11-13
8-K Results of Operations — earnings, may carry pipeline updates2026-11-12

Companies working on similar indications

Discussion

No messages yet. If you follow NKTR, you can start the conversation.
Track NKTR in real time
See live implied volatility for NKTR and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on NKTR
Contact — questions or corrections about NKTR: dukeupt@gmail.com